Ipamorelin vs GHRP-2: Growth Hormone Secretagogue Comparison for Researchers (2026)

Ipamorelin vs GHRP-2: Growth Hormone Secretagogue Comparison for Researchers (2026)

Ipamorelin and GHRP-2 are both members of the growth hormone releasing peptide (GHRP) family, yet they represent fundamentally different engineering philosophies: GHRP-2 achieves potent GH release, with broader hormonal effects, while ipamorelin achieves selective GH stimulation with a cleaner side-effect profile (PMID: 30136411). For researchers designing studies involving the somatotropic axis, choosing between them depends on whether GH pulse magnitude or endocrine selectivity is the primary experimental variable.

This comparison covers receptor pharmacology, GH release profiles, cortisol and prolactin effects, appetite stimulation, dosing protocols, pricing, and research applications for each compound.

Quick Comparison: Ipamorelin vs GHRP-2

Background: What Are GHRPs?

Growth Hormone Releasing Peptides are synthetic compounds that stimulate pituitary GH secretion by acting as agonists at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Unlike growth hormone-releasing hormone (GHRH), which works through the GHRH receptor, GHRPs achieve GH release through the ghrelin pathway.

The GHRP family has evolved across multiple generations, each iteration refining selectivity and reducing unintended endocrine effects:

• •GHRP-6 (first-generation): potent GH release, strong appetite stimulation via ghrelin-like effects, cortisol elevation
• •GHRP-2 (second-generation): improved GH potency over GHRP-6, reduced but still present appetite stimulation, cortisol elevation remains
• •Hexarelin (second/third-generation): most potent GHRP for GH release, significant cortisol and prolactin effects
• •Ipamorelin (fifth-generation): highly selective GH stimulation, minimal off-target hormonal activity

Ipamorelin: Research Profile

Ipamorelin (INN; research name NNC 26-0161) is a synthetic pentapeptide developed by Novo Nordisk in the late 1990s. Its sequence — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — incorporates non-natural amino acid substitutions that confer both metabolic stability and receptor selectivity.

Pharmacological Selectivity

This makes ipamorelin the only GHRP that behaves as a truly GH-selective secretagogue in a research context, enabling investigators to study GH axis dynamics without the confounding effects of simultaneous cortisol and prolactin elevation.

GH Release Mechanism

Ipamorelin acts as a GHS-R1a agonist with moderate intrinsic activity. It produces pulsatile GH release mimicking the physiological pattern — smaller amplitude peaks compared to GHRP-2, but episodic and patterned rather than supraphysiological. Its half-life of approximately 2 hours produces a well-defined GH pulse window suitable for time-course studies.

Research Applications

Ipamorelin is particularly suited to:

• •Long-term GH axis modulation studies (minimal hormonal confounds accumulate over time)
• •Body composition research requiring clean GH signaling
• •Studies of GHS-R1a receptor pharmacology
• •Pediatric growth research models (clean profile reduces unintended effects on HPA axis)
• •Combined GHRH+GHRP protocols where specificity is required (most commonly combined with CJC-1295)

GHRP-2: Research Profile

GHRP-2 (pralmorelin, KP-102, also GHRP-II) is a synthetic hexapeptide: D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂. It was developed as an improved analog of GHRP-6 with enhanced potency and reduced gastrointestinal side effects.

Pharmacological Activity

GHRP-2 is the most potent GHRP after hexarelin in terms of peak GH stimulation. It produces substantially larger GH pulses than ipamorelin at equimolar doses. This potency comes at the cost of off-target activity: GHRP-2 reliably elevates both cortisol and prolactin through concurrent activation of pathways beyond GHS-R1a.

GH Release Mechanism

GHRP-2 activates GHS-R1a with higher efficacy than ipamorelin, producing supraphysiological GH peaks in animal models. The GH pulse following GHRP-2 injection is both larger in magnitude and more rapid in onset compared to ipamorelin, typically peaking within 15–20 minutes.

Importantly, GHRP-2's GH-stimulating effects are synergistic with GHRH. When combined with CJC-1295 or Sermorelin, the combined GH pulse exceeds what either compound achieves alone — an effect that also holds for ipamorelin but is more pronounced with GHRP-2 due to its higher intrinsic activity.

Appetite and Ghrelin Pathway

GHRP-2 produces moderate appetite stimulation through its ghrelin-receptor agonism, less pronounced than GHRP-6 but more significant than ipamorelin. This effect can be a confounding variable in metabolic studies or, alternatively, the target of investigation in appetite regulation research.

Research Applications

GHRP-2 is particularly suited to:

• •Acute GH pulse studies requiring maximum GH output
• •Diagnostic testing protocols (GH deficiency assessment in clinical research)
• •Studies investigating GHRP effects on cortisol and HPA axis activity (where cortisol elevation is part of the model)
• •Short-term, high-intensity GH stimulation protocols
• •Research where GH pulse magnitude, not selectivity, is the primary endpoint

Head-to-Head: Key Comparisons

GH Release Potency

Winner: GHRP-2

In direct comparison studies, GHRP-2 consistently produces larger peak GH values than ipamorelin at equivalent doses. The magnitude difference is estimated at approximately 1.5–2.5x in terms of peak GH AUC (area under the curve). For researchers where maximum GH stimulation is the experimental objective, GHRP-2 delivers a stronger signal.

However, ipamorelin's smaller, cleaner GH pulse is arguably more physiologically relevant and less likely to saturate downstream GH signaling pathways during repeated administration in chronic studies.

Cortisol/HPA Axis Effects

Winner: Ipamorelin (for selectivity research)

Ipamorelin: No clinically significant ACTH or cortisol elevation has been documented at any research dose tested ([Raun et al., 1998]()).

GHRP-2: Consistent cortisol elevation (~45% above baseline) following administration. This represents a meaningful confounding variable in any study measuring stress hormones, immune function, or HPA axis markers.

If cortisol elevation would confound your experimental read-out, ipamorelin is the clear choice. If you are specifically investigating the relationship between GH secretagogues and HPA axis reactivity, GHRP-2's cortisol effects become an asset rather than a liability.

Prolactin Effects

Winner: Ipamorelin

Ipamorelin shows minimal prolactin elevation at research doses. GHRP-2 produces moderate prolactin increases, particularly at higher doses. For studies involving reproductive endocrinology, lactation research, or any endpoint that could be confounded by prolactin changes, ipamorelin's clean profile is advantageous.

Appetite and Ghrelin Effects

Winner: Ipamorelin (for selectivity)

GHRP-2 stimulates appetite moderately (less than GHRP-6). Ipamorelin shows minimal appetite effects at standard doses. For metabolic studies, energy intake measurements, or body composition research, ipamorelin's neutral effect on appetite reduces a significant confounding variable.

Duration of Effect

Similar for both

Both peptides have half-lives of approximately 1–2 hours, producing GH pulses that return to baseline within 3–4 hours. Ipamorelin may have a slightly longer half-life, but the clinical difference is minimal. Both are typically dosed 2–3 times daily in research protocols.

Safety Profile

Both favorable; Ipamorelin slightly cleaner

Neither GHRP-2 nor ipamorelin has demonstrated significant toxicity in preclinical research. GHRP-2's cortisol elevation, while not toxic, represents a physiological stress response that may compound over time in chronic studies. Ipamorelin's lack of HPA axis activation makes it the lower-risk option for sustained studies.

Dosing Protocols in Research

Both peptides share similar dosing parameters in preclinical and early-phase clinical research:

Standard Research Dosing:

Important Note on Timing: Both GHRPs are more effective in a fasted state or at least 2–3 hours after the last meal. High blood glucose and elevated free fatty acids suppress GH pulsatility and reduce GHRP responsiveness.

Stacking With GHRH Analogs

The most studied GHRP protocols combine them with a GHRH analog (CJC-1295, Sermorelin, or MOD-GRF 1-29). The synergistic mechanism: GHRH analogs prime the somatotroph cells for GH release, while GHRPs provide the triggering signal through the separate ghrelin pathway. Combined, they produce GH pulses 4–10x larger than either compound alone.

For GHRH + GHRP Combinations:

• •CJC-1295 (DAC) + Ipamorelin: Classic combination for sustained GH elevation; ipamorelin's selectivity keeps the protocol clean
• •CJC-1295 (no DAC/MOD-GRF 1-29) + GHRP-2: Acute, high-magnitude GH pulse for studies requiring maximal GH stimulation
• •CJC-1295 + Ipamorelin + GHRP-2 triple stack: Used in some research designs to maximize both GH output and selectivity

Our peptide comparison tool allows researchers to compare vendor pricing for these combinations.

Ipamorelin vs GHRP-2: Pricing Comparison (2026)

Both peptides are priced similarly, with modest differences based on synthesis complexity and market competition.

Ipamorelin — Market Range (2026):

GHRP-2 — Market Range (2026):

GHRP-2 is generally 10–15% less expensive than ipamorelin due to slightly simpler synthesis requirements. Both are among the more cost-effective peptides for GH axis research.

→ View current verified pricing and COA documentation at our Ipamorelin Supplier Comparison and GHRP-2 Supplier Comparison.

When to Choose Ipamorelin

Choose ipamorelin when:

• •Long-term or chronic dosing protocols are required — the lack of cortisol elevation avoids HPA axis sensitization over time
• •Metabolic or body composition studies where appetite confounds must be controlled
• •Selectivity is paramount — you need clean GH stimulation without concurrent cortisol/prolactin changes
• •CJC-1295 combination protocols are the primary design (the most researched GHRP pairing)
• •Endocrine baseline studies where any HPA perturbation would contaminate results
• •Pediatric models where HPA axis sensitivity is elevated

When to Choose GHRP-2

Choose GHRP-2 when:

• •Maximum GH pulse magnitude is the primary endpoint
• •Short-term, acute GH stimulation protocols are used (cortisol elevation less impactful in single-session designs)
• •HPA axis investigation is part of the study (GHRP-2's cortisol elevation becomes a research variable)
• •Diagnostic-type protocols modeled on GH stimulation tests
• •Appetite regulation research where ghrelin-pathway effects are the target
• •Budget-sensitive protocols where GHRP-2's slightly lower cost is relevant at scale

Can Ipamorelin and GHRP-2 Be Used Together?

Yes, and this combination is used in some research settings. The rationale: GHRP-2 provides a large GH pulse while ipamorelin may contribute complementary GHS-R1a effects. However, the practical benefit over using GHRP-2 alone is debated in the literature.

A more pharmacologically rational approach is combining either GHRP with a GHRH analog (CJC-1295, Sermorelin) rather than stacking two GHRPs, since GHRPs and GHRH analogs work through distinct receptors with synergistic mechanisms.

If using both in a triple stack (GHRH analog + GHRP-2 + ipamorelin), reduce individual GHRP doses proportionally to avoid excessive GH stimulation and cortisol response from GHRP-2.

FAQ: Ipamorelin vs GHRP-2

Q: Which is stronger, ipamorelin or GHRP-2?

GHRP-2 produces larger peak GH pulses at equivalent doses. Ipamorelin is more selective and produces a physiologically cleaner GH response. "Stronger" depends on whether you're measuring GH output or endocrine selectivity.

Q: Does ipamorelin elevate cortisol?

No. The pivotal Raun et al. (1998) study demonstrated that ipamorelin does not meaningfully elevate ACTH, cortisol, or prolactin even at doses far exceeding the therapeutic range — the key distinguishing feature of this peptide.

Q: Does GHRP-2 increase appetite?

Moderate appetite stimulation has been documented with GHRP-2, less than GHRP-6 but more than ipamorelin. This occurs through ghrelin receptor activation, which has known appetite-stimulating effects.

Q: Is ipamorelin or GHRP-2 better for CJC-1295 stacking?

Ipamorelin is the more commonly studied and commercially favored partner for CJC-1295 due to its clean selectivity profile. CJC-1295 + Ipamorelin is the dominant GHRH/GHRP combination in research literature.

Q: Can GHRP-2 be used for GH deficiency diagnosis research?

Yes. GHRP-2 has been used as a GH stimulation test agent in clinical research protocols, given its potent and reliable GH-releasing action. Its cortisol co-elevation actually mirrors some diagnostic test conditions.

Q: How long do the GH effects last?

Both peptides produce GH pulses lasting approximately 2–3 hours from injection, with peak at 15–30 minutes. Neither produces sustained GH elevation. Sustained GH axis stimulation requires multiple daily doses or combination with long-acting GHRH analogs like CJC-1295 DAC.

Q: Which is more affordable for long-term research?

GHRP-2 is typically 10–15% less expensive than ipamorelin. For multi-month protocols with frequent dosing, GHRP-2 offers modest cost savings. Both are among the more affordable research peptides per milligram.

Q: What is ipamorelin's mechanism of selectivity?

The exact structural basis for ipamorelin's GH selectivity is not fully characterized, but it is believed to involve subtle differences in GHS-R1a binding kinetics and downstream signaling bias that preferentially activates GH secretion pathways without triggering the cortisol/prolactin cascades engaged by other GHRPs.

---

Further Reading:

• •GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin — A Complete Research Guide (2026)
• •GHRP-2 (Pralmorelin): The Potent Second-Generation Growth Hormone Secretagogue — Complete Research Profile
• •Ipamorelin vs GHRP-6: Research Comparison Guide 2026
• •Best Peptides for Muscle Growth Research: Growth Hormone Secretagogues (2026)
• •Peptide Stack Builder
• •Dosage Chart

---

*All peptides on this page are sold

References

• •PMID: 39043357
• •PMID: 30282322
• •PMID: 42395176

for research purposes only. Not for human use. Peptides.SO does not provide medical advice.*

Pricing data from Peptides.SO vendor database. See GHRP research guide for a 4-way GHRP comparison including hexarelin and GHRP-6.